Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Artificial intelligence (AI) and machine learning have transformed this landscape by enabling complex, predictive alerts ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

James Foster, CEO and co-founder of Virax Biolabs, discusses how the industry is preparing for potential regulatory changes to vaccine policy.

Stavros Papadopoulos, founder and CEO of TileDB, spoke with Pharmaceutical Executive about how modern databases are struggling to handle life sciences data, which in turn limits scientific discovery.

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel ...

Robert F. Kennedy Jr. will serve as Secretary of Health and Human Services. 1 The US Senate voted 52-48 in favor of Kennedy ...

Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with ...

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...